SecBot SecBot
8-K ·Filed May 8, 2026

CGON

CG Oncology, Inc.
MIXED
Impact 5/10
Horizonweeks Processed6mo ago SEC0001193125-26-213440
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The stock will trade on the PIVOT-006 topline data and CORE-008 Cohort CX results expected in the coming weeks, not on the quarterly financials. The BLA completion timeline extension to Q4 2026 removes near-term regulatory catalyst risk but provides clarity. Monitor the AUA presentation on May 16 for the first combination data with gemcitabine.

DirectionMixed
Confidencemedium
Horizonweeks

Price Chart

Loading chart...

Executive Summary

CG Oncology reported Q1 2026 results with a net loss of $0.71 per share, wider than the prior year's $0.45 loss, and total revenue of $1.1M. The key positive was a BLA submission timeline update for cretostimogene in HR BCG-unresponsive NMIBC, now expected to complete in Q4 2026, and a strong cash position of $1.1B. However, the widening net loss and lack of consensus estimates for this quarter make the financial results directionally negative for a pre-revenue biotech.

Key Financial Metrics

EPS
−$0.71
Revenue
$1.1M
+1982.7% YoY
Rating
in line

Key Facts

  • BLA completion for cretostimogene in HR BCG-unresponsive NMIBC expected Q4 2026, following FDA alignment discussions
  • PIVOT-006 Phase 3 topline data in intermediate-risk NMIBC anticipated H1 2026
  • CORE-008 Cohort CX Phase 2 first results to be presented at AUA 2026 on May 16
  • Cash, cash equivalents and marketable securities of $1.1B as of March 31, 2026, up from $742.2M at Dec 31, 2025
  • Net loss of $60.2M ($0.71/share) for Q1 2026 vs $34.5M ($0.45/share) in Q1 2025
  • R&D expenses increased to $43.7M from $27.5M; G&A expenses increased to $20.8M from $14.8M
  • Raised $391.4M net proceeds from ATM facility in Q1 2026, selling 6,941,407 shares
  • Total revenues of $1.1M for Q1 2026 vs $52K in Q1 2025, primarily from commercial and development revenue

Financial Impact

Net loss widened by 74.7% YoY to $60.2M; cash position strengthened by $334M sequentially to $1.1B

net losscash positionR&D expensesG&A expenses

Risk Factors

  • PIVOT-006 Phase 3 topline data may miss efficacy or safety endpoints
  • BLA submission delay beyond Q4 2026 could push potential approval into 2027
  • Widening net losses with no near-term revenue visibility; cash burn rate increased to ~$60M/quarter
  • Dilution risk from continued ATM usage (6.9M shares sold in Q1 2026)

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
95% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-213440
Document: ck0001991792-20260508.htm0001193125-26-213440
Document: 0001193125-26-213440-index-headers.html0001193125-26-213440
Document: 0001193125-26-213440-index.html0001193125-26-213440
Document: 0001193125-26-213440.txt0001193125-26-213440
8-K Data (Synthetic)0001193125-26-213440

Track record

25 reports on CGON

Performance horizon

6 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +26.33% at T+20 after the Jun 12, 2026 report. 8 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today 8-K Bullish 7/10 Entry $98.84 Now $84.78 −14.23% settles Dec 15
  2. Nov 16, 2026today Press Release Bullish 7/10 Entry $95.01 Now $84.78 −10.77% settles Dec 15
  3. Nov 6, 202610d ago 8-K Bearish 5/10 Entry $75.99 Now $84.78 −11.57% settles Dec 7
  4. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $75.99 Now $84.78 +11.57% settles Dec 7
  5. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $64.06 Now $84.78 +32.34% settles Dec 2
  6. Oct 19, 202628d ago 3 Neutral 2/10 Entry $61.93 Now $84.78 +36.90% settles Nov 17
  7. Oct 15, 20264w ago 144 Neutral 2/10 Entry $59.85 to $74.40 Now $84.78 +41.65% ▲ +24.31% +25.47% vs SPY
  8. Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $63.13 to $74.74 Now $84.78 +34.29% ▲ +18.39% +21.66% vs SPY
  9. Aug 6, 202614w ago Press Release Bearish 7/10 Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
  10. Aug 6, 202614w ago 424B5 Bearish 6/10 Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 6h 22m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 8, 2026